StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Aromasin (exemestane) [legacy through FY25] by Quarter

Aromasin (exemestane) [legacy through FY25] ($M) ($M)

QuarterlyAnnual

Pfizer Aromasin (exemestane) [legacy through FY25]: $117M in Q4 2025, up 30.0% from a year earlier. That is the highest of the 24 quarters on record here.

Latest, Q4 2025
117
Period ended Dec 31, 2025
Change on a year earlier
+30.0%
90 in Q4 2024
History
24 quarters
Since Q1 2020
Sources
15
Documents cited below

Where the Q4 2025 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2026-02-26) ↗

Reported in Form 10-K Segment Note.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAromasin (exemestane) [legacy through FY25] ($M) ($M)Year on yearSource
Q4 2025Dec 31, 2025117+30.0%Form 10-K (filed 2026-02-26) ↗
Q3 2025Sep 28, 2025114+31.0%Form 10-Q (filed 2025-11-04) ↗
Q2 2025Jun 29, 2025111+27.6%Form 10-Q (filed 2025-08-05) ↗
Q1 2025Mar 30, 2025108+31.7%Form 10-Q (filed 2025-05-05) ↗
Q4 2024Dec 31, 202490+18.4%Form 10-K (filed 2026-02-26) ↗
Q3 2024Sep 29, 202487+14.5%Form 10-Q (filed 2025-11-04) ↗
Q2 2024Jun 30, 202487+20.8%Form 10-Q (filed 2025-08-05) ↗
Q1 2024Mar 31, 202482+6.5%Form 10-Q (filed 2025-05-05) ↗
Q4 2023Dec 31, 202376+24.6%Form 10-K (filed 2026-02-26) ↗
Q3 2023Oct 1, 202376+15.2%Form 10-Q (filed 2023-11-08) ↗
Q2 2023Jul 2, 202372+22.0%Form 10-Q (filed 2023-08-09) ↗
Q1 2023Apr 2, 202377+24.2%Form 10-Q (filed 2023-05-10) ↗
Q4 2022Dec 31, 202261+17.3%Form 10-K (filed 2024-02-22) ↗
Q3 2022Oct 2, 202266+17.9%Form 10-Q (filed 2023-11-08) ↗
Q2 2022Jul 3, 202259+15.7%Form 10-Q (filed 2023-08-09) ↗
Q1 2022Apr 3, 202262+19.2%Form 10-Q (filed 2023-05-10) ↗

Cite this data

StockData. (2026). Pfizer Aromasin (exemestane) [legacy through FY25] ($M), quarterly Q1 2020–Q4 2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/aromasin-leg

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.